India, March 1 -- Cullinan Oncology, Inc. (CGEM) announced the FDA has cleared its Investigational New Drug application for CLN-619 in relapsed/refractory multiple myeloma. The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.
Jeffrey Jones, Chief Medical Officer, Cullinan Oncology, said: "This Phase 1 trial will assess CLN-619 in patients with multiple myeloma, and, given the safety profile shown to date for CLN-619, we believe there is an opportunity to combine the monoclonal antibody with multiple standard therapies."
CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to the stress-induced ligands MICA and MICB.
For More Such Health News, visit rttnews.com.
For comme...